RAC race oncology ltd

2.11%

$1.16

CPACS: Research, Results, Market Comparisons, and Valuations, page-3

First 3 Last

Share
Profile

Follow
Boffin99

3,449 Posts.

3229

12/07/24

20:24

Post #: 74733608
Share

Originally posted by Mason14: ↑

I thought a dedicated thread for CPACS was required.

I think I have discovered a reason outside m6A levels for the lead-in dose of Bisantrene 7-days prior to the combination.

Below is a 1984 abstract investigating the immunomodulating effects of Bisantrene. The paper found that providing 6 and 12 mg/kg Bisantrene 5 or 15 days prior to tumor implantation produced greater increases in life span and numbers of long-term survivors than a standardised therapeutic fashion of 100 mg/kg on day +1. Durr suggests this is through macrophage activation, where M1 macrophage activity has been consistently shown to demonstrate anti-tumor as well as anti-bacterial effects.

6 mg/kg in mice converts to 18 mg/m² in humans
12 mg/kg in mice converts to 36 mg/m² in humans
100 mg/kg in mice converts to 300 mg/m² in humans

Below is work completed by Wang et al 1986 investigating bisantrene-activated macrophages in a number of tumor xenograft models, where bisatrene-activated macrophages significantly improved survival in murine models. The figures depict bisantrene-activated macrophages given as a single dose at day 0 (top left) and day 4 (top right), and multiple doses on days 7 and 14 (bottom left) and days 3, 9, and 14 (bottom right).

More work by Wang in 1984 indicates that a 50 mg/kg dose of Bisantrene in mice is the optimal macrophage-stimulating dose, which equates to approximately 150 mg/m2 in humans.

He further demonstrated that a 100 mg/kg (300 mg/m2) dose activated >80% cytostatic macrophages for 2-weeks, and significantly for up to 4-weeks.

FTO inhibition/knockdown has been shown to ablate M1 macrophage activation, which means M1 macrophage activation is happening independent of FTO inhibtion. With the inclusion of M1 macrophage activation, Bisantrene has at least 5 therapeutic targets in vivo including FTO, DNA, telomerase, cardioprotection MoA, and now M1 macrophage activation. This concept may seem strange today where compounds are highly selective, but it was very common for the era in which Bisantrene was produced (e.g. doxorubicin). Because chemotherapy was typically a single agent treatment, compounds were ranked based on the broadness of their activity. The extremely interesting thing for me is how 6 mg/kg of Bisantrene in mice was sufficient to significantly increase M1 macrophage activity, which would imply a very low concentration requirement for the activation of this system.

Something which I only became aware of because of @Boffin99 excellent research, RAC have included Abraxane (nab-paclitaxel) as an example of a reformulation. Paclitaxel is primarily a microtubule inhibitor, but has been shown to have immunomodulatory effects that reduce tumor growth by reprogramming tumor-associated macrophages to an M1 profile in a TLR4-dependent manner. Coincidence? I think not!

If this is something that translates to humans, it explains Bisantrene being used 7-days before the Bis+Dox combination in the upcoming P1a/b trial. They are probably going to measure macrophage activity/polarization as well as m6A levels. There really is so much to learn about this drug!

Expand

These results have been more recently reproduced as part of the Melanoma PD-1 preclinicals. So not just some old papers from 1986, and, provides cancer killer power where other anti-PD1 therapy is ineffective so has commercial application. Perhaps a Bisantrene + Keytruda combo in the future?...

RAC Price at posting: $1.94 Sentiment: Buy Disclosure: Held
81 Upvote

23 Great analysis

Reply

Top Stories

ASX Market Close: Why are we red today? Because US CPI's at 3%

LIS

Li-S Energy the latest microcap to pivot to US defence market

LDX

Lumos Diagnostics surges 140% on major US contract deal

LU7

Lithium Universe targets silver boom with breakthrough solar recycling tech

Listen: HotCopper Wire Podcast 018 – Potatoes, TACOs, and the $120M helicopter heist

There are more pages in this discussion • 168 more messages in this thread...

First 3 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $1.16		Change -0.025(2.11%)		Mkt cap ! $201.5M

Open	High	Low	Value	Volume
$1.17	$1.19	$1.16	$39.17K	33.62K

Buyers (Bids)

No.	Vol.	Price($)
1	3560	$1.16

Sellers (Offers)

Price($)	Vol.	No.
$1.19	4359	2

View Market Depth

No.	Vol.	Price($)
1	3560	1.160
2	10624	1.150
5	12426	1.140
3	19786	1.130
3	6677	1.125

Price($)	Vol.	No.
1.185	4359	2
1.195	1855	2
1.200	1470	1
1.220	4060	1
1.230	2500	1

Last trade - 16.10pm 16/07/2025 (20 minute delay)

RAC (ASX) Chart

CPACS: Research, Results, Market Comparisons, and Valuations, page-3

ASX Market Close: Why are we red today? Because US CPI's at 3%

Li-S Energy the latest microcap to pivot to US defence market

Lumos Diagnostics surges 140% on major US contract deal

Lithium Universe targets silver boom with breakthrough solar recycling tech

Listen: HotCopper Wire Podcast 018 – Potatoes, TACOs, and the $120M helicopter heist

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

CPACS: Research, Results, Market Comparisons, and Valuations, page-3

Top Stories

ASX Market Close: Why are we red today? Because US CPI's at 3%

Li-S Energy the latest microcap to pivot to US defence market

Lumos Diagnostics surges 140% on major US contract deal

Lithium Universe targets silver boom with breakthrough solar recycling tech

Listen: HotCopper Wire Podcast 018 – Potatoes, TACOs, and the $120M helicopter heist

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News